Table 11.1.3Comparison of Results for Direct and Indirect Analysis of Mortality

Indirect comparisons in the upper triangle, direct comparisons in the lower triangle.

Indirect comparision

Direct comparison
carbapenemUridipenicillin3G cef4G cefUridipenicillin + aminoglycoside3G cef + aminoglycoside4G cef + aminoglycoside
carbapenem @@@@ 1.75 1.190.850.970.930.79
@@@@ 1.14 to 2.63 0.84 to 1.610.6 to 1.230.71 to 1.30.65 to 1.330.39 to 1.85
uridipenicillin 0.4@@@@0.67 0.49 0.55 0.53 0.45
0.115 to 1.388@@@@0.44 to 1.1 0.32 to 0.78 0.37 to 0.83 0.34 to 0.88 0.2 to 1.23
3G cef 0.9971.178@@@@@0.710.820.80.68
0.597 to 1.6640.072 to 19.167@@@@@0.51 to 1.080.59 to 1.110.54 to 1.120.32 to 1.61
4G cef 1.3681.561.558@@@@1.141.120.93
0.714 to 2.6240.73 to 3.330.937 to 2.589@@@@0.75 to 1.690.68 to 1.640.47 to 2.08
uridipenicillin+aminoglcoside 1.0041.4881.247@@@@@0.980.83
0.565 to 1.7860.859 to 2.5760.903 to 1.722@@@@@0.65 to 1.430.39 to 2.04
3G cef + aminoglycoside 1.0652.1551.2040.593@@@@0.85
0.691 to 1.6410.871 to 5.3330.685 to 2.1180.07 to 4.996@@@@0.4 to 2.13
4G cef + aminoglycoside 1.696@@@@@
0.154 to 18.673@@@@@

From: Initial Treatment: guideline chapter six

Cover of Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients
Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients.
NICE Clinical Guidelines, No. 151.
National Collaborating Centre for Cancer (UK).
Copyright © National Collaborating Centre for Cancer, 2012.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.